Vida Diagnostics announced that it received FDA 510(k) clearance for enhancements to its AI-based LungPrint solution.
Enhancements involved in the clearance include automated deep learning-based lung and lobe segmentation algorithms, which the company said further validates its products’ quality and clinical efficacy, according to a news release.
LungPrint’s algorithms allow the company to improve its lung imaging analysis offerings to allow for physicians to develop personalized treatment plans. The deep-learning algorithms improve the automated segmentation of the lung and lobes for greater clinical and diagnostic precision.
Vida’s algorithms learn how to analyze lung scans based on intelligence derived from the database the company has amassed over the years.
“We’re living in the age of personalized medicine, where precision algorithms can be used to optimize outcomes for patients,” said Susan Wood, PhD, president and CEO of VIDA. “The addition of deep-learning capabilities to our already-proven solution is a critical step towards diagnosing and treating lung disease with anatomical precision based on clinical best practices.”